PHAT

Phathom Pharmaceuticals Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth↓ 4/10
  • Value↓ 0/10
Phathom Pharmaceuticals sales and earnings growth
PHAT Growth
Neutral
  • Revenue Y/Y↑ 216.93%
  • EPS Y/Y↑ 42.72%
  • FCF Y/Y↑ 37.43%
Phathom Pharmaceuticals gross and profit margin trends
PHAT Profitability
Good
  • Gross margin ↑ 87.10%
  • EPS margin↓ -126.30%
  • ROIC 5Y↓ -57.06%
Phathom Pharmaceuticals net debt vs free cash flow
PHAT Risk
Poor
  • Debt / Equity↑ 999.0
  • Debt / FCF↓ 2.6
  • Interest coverage↓ -2.2

Phathom Pharmaceuticals stock volatility is in-line with the overall market. We give it a Poor risk rating.

More Biotechnology stocks ↗